Pillar Biosciences Closes $29.7 Million in Series C Financing

Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization


Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, today announced the closing of a $29.7 million Series C preferred stock financing. The financing will accelerate the expansion of Pillar’s in vitro diagnostic and research use only panels and advance Pillar’s global commercial outreach.

Pillar’s flagship technology, SLIMamp® target enrichment chemistry, enables automatable amplification of overlapping amplicons in a single tube from as little as 2.5ng DNA in less than 8 hours. Pillar’s complementary PiVAT® bioinformatics platform enables variant calling down to 1% VAF for virtually every type of variant with minimal computing resources and processing time.

For precision medicine to become widely accessible, pathologists need streamlined NGS workflows that deliver timely results, especially for first line cancer therapies. Pillar Biosciences’ technology and products focus on providing pathologists with productive solutions so that precision medicine can become the norm.

Recently, a Pillar custom product received approval from New York State Department of Health. Pillar was also granted CE approval for its first in vitro diagnostic panel, the Pillar® ONCO/Reveal® Dx Lung and Colon Cancer Assay, which guides the prescription of six different therapies simultaneously, reduces the need for repeat testing, and allows for treatment decisions in just 4 days.

Pillar Biosciences has made considerable progress towards ensuring global access to its suite of NGS panels and software. Pillar’s panels are compatible with Illumina®, Ion Torrent™, and MGI™ sequencing platforms. Pillar also recently secured distributors in Israel, Hong Kong, Macau, South Korea, and ASEAN countries.

“We are proud of what our customers have been able to accomplish with Pillar’s technology,” said Dr. Gang Song, founder and CEO of Pillar Biosciences. “Now we are building IVD products that will be accessible to every pathologist, so that every cancer patient can get the right therapy the first time.”

“We are a strong believer in using NGS tumor testing to make precision medicine the first line treatment,” said Simone Song, Senior Partner of ORI Healthcare Fund, which invested in Pillar’s Series A round and also led the Series C round. “Pillar’s SLIMamp® technology is fast, accurate, user friendly, and cost effective. We have confidence that Pillar will fulfill an unmet medical need and thus bring true benefits to cancer patients.”

Press Contact

William Wright
Director of Sales

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®– and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.

Learn more at https://pillar-biosciences.com.

About ORI Healthcare Fund L.P.

ORI Healthcare Fund is a $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The General Partner of the Fund was founded by Ms. Simone (Hong Fang) Song, the former head of China Healthcare Investment Banking at Goldman Sachs.

Don’t Stop Here

More To Explore

This small academic lab ramped up in-house NGS testing despite limited resources, and you can too

“There has been sort of this push to make genomics a send-out endeavor…and we are pushing back.” Dr. Cynthia Schandl is the director of a …

Read More →

Pillar Biosciences Closes $29.7 Million in Series C Financing

Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, …

Read More →

Finding flexibility in a resource limited world: Online presentation

Time and resource optimization are top-of-mind for many clinical labs working with NGS. As a resource for clinical researchers and labs, we revisit this presentation …

Read More →
Four people smile out of the screen from their lab stations.

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories

Increasingly, clinical samples of all types are being analyzed with the goal of matching patients to target therapies. In the summer of 2017, Thermo Fisher received …

Read More →
Top 5 reasons to go custom with Pillar Biosciences in graphic font

5 reasons to go custom with your next sequencing panel

Off-the-shelf next-generation sequencing (NGS) panels save on sequencing costs by targeting specific genes, and the smaller resulting datasets are easier to analyze. The catch is, …

Read More →
a graphic that reads "Garbage in, Greatness out" next to a photo of a tumor sample embedded in parafin wax for analysis

Garbage in, greatness out: making the most of FFPE samples

The cancer research community relies on formalin-fixed samples, but the quality of these samples degrades over time. Sequencing data from partially degraded samples is plagued …

Read More →
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top